

North America Biotechnology And Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report By Service (Consulting, Regulatory Affairs), By End Use, By Country, And Segment Forecasts, 2024 - 2030

https://marketpublishers.com/r/N94437D6B1DAEN.html

Date: July 2024

Pages: 110

Price: US\$ 4,950.00 (Single User License)

ID: N94437D6B1DAEN

Abstracts

This report can be delivered to the clients within 2 Business Days

North America Biotechnology and Pharmaceutical Services Outsourcing Market Growth & Trends

The North America biotechnology and pharmaceutical services outsourcing market size is expected t%li%reach USD 16.81 billion by 2030, according t%li%a new report by Grand View Research, Inc., growing at a CAGR of 5.13% from 2024 t%li%2030.

Increasing competition t%li%launch novel molecules with better RoI is expected t%li%heighten the demand for CRO service providers across the globe. Pharmaceutical companies face complexity in regulations along with increased research costs, creating a need for expertise in numerous portfolios and driving the need for outsourcing in the market. With increasing clinical trial privatization, there has been an increase in outsourcing functions t%li%CROs and CDMOs t%li%focus on core capabilities. Pharmaceutical and biotechnology companies have started outsourcing R&D activities, which are complex and need a strict timeline t%li%follow up. A CRO's function is t%li%bring new products t%li%the market as per the timeline given by the client. CROs have the required infrastructure and skilled expertise, which provides several advantages associated with cost, time, and efficiency. The cost saved helps in offering the best savings for sponsors and patients.



Drug discovery and development is an integral strategy adopted by pharmaceutical and biotechnology companies. An increase in the prevalence of chronic and long-term diseases led t%li%a rise in the demand for extensive R&D investments in the drug development process. Growing clinical trial failure rates coupled with increasing drug development costs lead t%li%huge losses in revenue for manufacturers. Setbacks faced in clinical studies have led smaller pharmaceutical companies t%li%g%li%bankrupt. Many private investors have been observed t%li%withdraw venture capital support from startup drug companies, considering their investments would suffer if there were a disruption in the drug development process. T%li%circumvent these situations and gain a substantial return on investment, pharmaceutical companies are now adopting computational biology-based predictive models over traditional methods of clinical trials, which are expected t%li%drive market growth during the forecast period. Insights gained from subject-matter experts, R&D executives, and clinical professionals help a company save a large amount, which can be spent on R&D, thereby boosting demand for consulting services.

The healthcare outsourcing industry has recently witnessed a surge in mergers and acquisitions. The sector's rapid growth and promising potential have attracted significant investment from pharmaceutical companies, biotech firms, & venture capitalists. As a result, companies seek t%li%expand their portfolios and capabilities through strategic acquisitions t%li%capitalize on emerging opportunities and strengthen their competitive position in the market. For instance, in May 2024, Sartorius AG announced a collaboration with NVIDIA t%li%help the development of new therapies, leveraging NVIDIA's AI-powered computing software and platform. Moreover, the complexity and high costs associated with developing therapeutics are leading t%li%increased collaboration & consolidation within the industry. Mergers & acquisitions offer companies complementary technologies, expertise, and resources, enabling them t%li%overcome development challenges, accelerate product development timelines, and enhance manufacturing capabilities.

North America Biotechnology And Pharmaceutical Services Outsourcing Market Report highlights

Based on service, the consulting segment held the largest revenue share in 2023. The large segment growth is owing t%li%the growing adoption of consulting services t%li%meet regulatory compliance, quality assurance,



remediation challenges, and strategic consulting requirements by sponsors. Furthermore, regulatory consulting services are widely used owing t%li%increasing fraud cases, discrepancies in Intellectual Property Rights (IPR), and rising technological innovation, which are some of the major challenges faced by pharmaceutical and biotechnology companies. Another factor driving the demand for consulting services is the consolidated nature of the market. which leads t%li%an increase in the number of joint ventures, takeovers, acquisitions, and mergers. Such factors are anticipated t%li%drive the market growth.

Based on end use, the pharmaceutical companies segment held the largest revenue share of over 57.79% in 2023. The segment growth is owing t%li%an increasing preference for outsourcing noncore activities such as clinical trials, data management, regulatory compliance, and manufacturing t%li%CROs and CMOs among pharmaceutical companies is anticipated t%li%boost segment revenue growth. Outsourcing t%li%CROs and CMOs provides pharmaceutical companies with cost-effective solutions compared t%li%maintaining extensive inhouse capabilities.

The U.S. dominated the biotechnology and pharmaceutical services outsourcing market with a share of 87.37% in 2023. The country's revenue growth is owing



t%li%high R&D spending on clinical trials, which is another major factor expected t%li%fuel market growth. For instance, in October 2021, the U.S. FDA approved 11 new clinical trial research, resulting in over USD 25 million in funding over the next four years. These grants aim t%li%support the development of new medical products specifically for treating rare diseases. The growing presence of these companies expanding their manufacturing capabilities t%li%cater t%li%the rising demand for pharmaceuticals is anticipated t%li%propel market growth.



Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
 - 1.4.1. Purchased Database
 - 1.4.2. GVR's Internal Database
 - 1.4.3. Secondary Sources
 - 1.4.4. Primary Research
- 1.5. Details of primary research
- 1.6. Market Formulation & Validation
- 1.7. Country-wise Market Calculation
 - 1.7.1. Country Wise Market: Base Estimates
 - 1.7.2. CAGR Calculation
 - 1.7.3. Country Based Segment Share Calculation
- 1.8. Model Details
 - 1.8.1. Commodity flow analysis (Model 1)
 - 1.8.2. Value Chain-Based Sizing & Forecasting (Model 2)
 - 1.8.3. QFD Model Sizing & Forecasting (Model 3)
 - 1.8.4. Bottom-up Approach (Model 4)
- 1.9. Research Scope and Assumptions
- 1.10. List of Secondary Sources
- 1.11. List of Primary Sources
- 1.12. List of Abbreviations
- 1.13. Objectives
 - 1.13.1. Objective
 - 1.13.2. Objective
 - 1.13.3. Objective
 - 1.13.4. Objective

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights



CHAPTER 3. NORTH AMERICA BIOTECHNOLOGY AND PHARMACEUTICAL SERVICES OUTSOURCING MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Market Lineage Outlook
 - 3.1.1. Parent Market Outlook
 - 3.1.2. Ancillary Market Outlook
- 3.2. Market Dynamics
 - 3.2.1. Market Driver Analysis
 - 3.2.1.1. Increasing Outsourcing of R&D Activities
 - 3.2.1.2. Changing Regulatory Landscape
 - 3.2.1.3. Increasing Focus on Core Competencies by Pharmaceutical and

Biotechnology Companies

- 3.2.1.4. Growing Drug Development Costs Coupled With High Clinical Development Failure Rates
- 3.2.1.5. Increasing Mergers and Collaborations
- 3.2.2. Market Restraint Analysis
 - 3.2.2.1. Monitoring Issues and Lack of Standardization
 - 3.2.2.2. Loss of Control
 - 3.2.2.3. Data Security Issues
- 3.3. Technology Landscape
- 3.4. Pricing Model Analysis
- 3.5. GxP Overview
 - 3.5.1. Good Manufacturing Practices (GMP)
 - 3.5.2. Current Good Manufacturing Practices (cGMP)
 - 3.5.3. Good Laboratory Practices (GLP)
 - 3.5.4. Good Clinical Practices (GCP)
 - 3.5.5. Good Distribution Practices (GDP)
- 3.6. Clinical Trials Volume Analysis (2023)
 - 3.6.1. Total Number of Clinical Trials, by Country
 - 3.6.2. Total Number of Clinical Trials, by Phase
 - 3.6.3. Total Number of Clinical Trials, by Study Design
 - 3.6.4. Total Number of Clinical Trials, by Key Therapeutic Area
- 3.7. R&D Investment Analysis
- 3.8. North America Biotechnology and Pharmaceutical Services Outsourcing Market Analysis Tools
 - 3.8.1. Porter's Five Forces Analysis
 - 3.8.2. PESTEL Analysis
- 3.9. COVID-19 Impact Analysis



CHAPTER 4. NORTH AMERICA BIOTECHNOLOGY AND PHARMACEUTICAL SERVICES OUTSOURCING MARKET: SERVICE ESTIMATES & TREND ANALYSIS

- 4.1. Segment Dashboard
- 4.2. North America Biotechnology and Pharmaceutical Services Outsourcing Market: Service Movement Analysis
- 4.3. North America Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
- 4.4. Consulting
- 4.4.1. Consulting Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.4.2. Regulatory Consulting
- 4.4.2.1. Regulatory Consulting Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.4.3. Clinical Development Consulting
- 4.4.3.1. Clinical Development Consulting Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.4.4. Strategic Planning & Business Development Consulting
- 4.4.4.1. Strategic Planning & Business Development Consulting Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
- 4.4.5. Quality Management Systems Consulting
- 4.4.5.1. Quality Management Systems Consulting Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.4.6. Others
- 4.4.6.1. Others Market Revenue Estimates and Forecasts, 2018 2030 (USD Million) 4.5. Regulatory Affairs
- 4.5.1. Regulatory Affairs Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.5.2. Legal Representation
- 4.5.2.1. Legal Representation Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.5.3. Regulatory Writing & Publishing
- 4.5.3.1. Regulatory Writing & Publishing Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.5.4. Product Registration & Clinical Trial Applications
- 4.5.4.1. Product Registration & Clinical Trial Applications Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.5.5. Regulatory Submissions
 - 4.5.5.1. Regulatory Submissions Market Revenue Estimates and Forecasts, 2018 -



- 2030 (USD Million)
 - 4.5.6. Regulatory Operations
- 4.5.6.1. Regulatory Operations Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.5.7. Others
 - 4.5.7.1. Others Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
- 4.6. Product Design & Development
- 4.6.1. Product Design & Development Market Revenue Estimates and Forecasts, 20182030 (USD Million)
 - 4.6.2. Research, Strategy, & Concept Generation
- 4.6.2.1. Research, Strategy, & Concept Generation Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
- 4.6.3. Concept & Requirements Development
- 4.6.3.1. Concept & Requirements Development Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
- 4.6.4. Detailed Design & Process Development
- 4.6.4.1. Detailed Design & Process Development Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.6.5. Design Verification & Validation
- 4.6.5.1. Design Verification & Validation Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.6.6. Process Validation & Manufacturing Transfer
- 4.6.6.1. Process Validation & Manufacturing Transfer Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.6.7. Production & Commercial Support
- 4.6.7.1. Production & Commercial Support Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
- 4.7. Auditing and Assessment
- 4.7.1. Auditing and Assessment Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.7.2. General Auditing
- 4.7.2.1. General Auditing Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
- 4.7.3. Gap Assessments
- 4.7.3.1. Gap Assessments Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.7.4. Due Diligence Assessments
- 4.7.4.1. Due Diligence Assessments Market Revenue Estimates and Forecasts, 20182030 (USD Million)



- 4.7.5. Mock Audits/Inspections
- 4.7.5.1. Mock Audits/Inspections Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.7.6. Inspection/Audit Management and Support
- 4.7.6.1. Inspection/Audit Management and Support Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
 - 4.7.7. Others
 - 4.7.7.1. Others Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
- 4.8. Product Maintenance
- 4.8.1. Product Maintenance Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
- 4.9. Training & Education
- 4.9.1. Training & Education Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
- 4.10. Others
- 4.10.1. Others Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)

CHAPTER 5. NORTH AMERICA BIOTECHNOLOGY AND PHARMACEUTICAL SERVICES OUTSOURCING MARKET: END-USE ESTIMATES & TREND ANALYSIS

- 5.1. Segment Dashboard
- 5.2. North America Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Movement Analysis
- 5.3. North America Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
- 5.4. Pharmaceutical Companies
- 5.4.1. Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)
- 5.5. Biotech Companies
- 5.5.1. Biotech Companies Market Revenue Estimates and Forecasts, 2018 2030 (USD Million)

CHAPTER 6. NORTH AMERICA BIOTECHNOLOGY AND PHARMACEUTICAL SERVICES OUTSOURCING MARKET: COUNTRY ESTIMATES & TREND ANALYSIS, BY SERVICE, BY END-USE

- 6.1. Country Dashboard
- 6.2. North America Biotechnology and Pharmaceutical Services Outsourcing Market: Country Movement Analysis



- 6.3. U.S.
 - 6.3.1. Key Country Dynamics
 - 6.3.2. Competitive Scenario
 - 6.3.3. Regulatory Framework
- 6.3.4. U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 2030 (USD Million)
- 6.4. Canada
 - 6.4.1. Key Country Dynamics
 - 6.4.2. Competitive Scenario
 - 6.4.3. Regulatory Framework
- 6.4.4. Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 2030 (USD Million)
- 6.5. Mexico
 - 6.5.1. Key Country Dynamics
 - 6.5.2. Competitive Scenario
 - 6.5.3. Regulatory Framework
- 6.5.4. Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 2030 (USD Million)
- 6.6. Puerto Rico
 - 6.6.1. Key Country Dynamics
 - 6.6.2. Competitive Scenario
 - 6.6.3. Regulatory Framework
- 6.6.4. Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 2030 (USD Million)

CHAPTER 7. COMPETITIVE LANDSCAPE

- 7.1. Company Categorization
 - 7.1.1. Market Leaders
 - 7.1.2. Emerging Players
- 7.2. Company Market Share/Assessment Analysis, 2023
- 7.3. Service Heat Map Analysis
- 7.4. Company Profiles
 - 7.4.1. Parexel International Corporation
 - 7.4.1.1. Company Overview
 - 7.4.1.2. Financial Performance
 - 7.4.1.3. Service Benchmarking
 - 7.4.1.4. Strategic Initiatives
 - 7.4.2. The Quantic Group



- 7.4.2.1. Company Overview
- 7.4.2.2. Financial Performance
- 7.4.2.3. Service Benchmarking
- 7.4.2.4. Strategic Initiatives
- 7.4.3. IQVIA
 - 7.4.3.1. Company Overview
- 7.4.3.2. Financial Performance
- 7.4.3.3. Service Benchmarking
- 7.4.3.4. Strategic Initiatives
- 7.4.4. Lachman Consultant Services, Inc.
 - 7.4.4.1. Company Overview
 - 7.4.4.2. Financial Performance
 - 7.4.4.3. Service Benchmarking
 - 7.4.4.4. Strategic Initiatives
- 7.4.5. GMP Pharmaceuticals Pty Ltd.
 - 7.4.5.1. Company Overview
 - 7.4.5.2. Financial Performance
 - 7.4.5.3. Service Benchmarking
 - 7.4.5.4. Strategic Initiatives
- 7.4.6. LabCorp
 - 7.4.6.1. Company Overview
 - 7.4.6.2. Financial Performance
 - 7.4.6.3. Service Benchmarking
 - 7.4.6.4. Strategic Initiatives
- 7.4.7. Charles River Laboratories
 - 7.4.7.1. Company Overview
 - 7.4.7.2. Financial Performance
 - 7.4.7.3. Service Benchmarking
 - 7.4.7.4. Strategic Initiatives
- 7.4.8. ICON plc.
 - 7.4.8.1. Company Overview
 - 7.4.8.2. Financial Performance
 - 7.4.8.3. Service Benchmarking
 - 7.4.8.4. Strategic Initiatives
- 7.4.9. Syneos Health
 - 7.4.9.1. Company Overview
 - 7.4.9.2. Financial Performance
 - 7.4.9.3. Service Benchmarking
 - 7.4.9.4. Strategic Initiatives



- 7.4.10. Lonza
 - 7.4.10.1. Company Overview
 - 7.4.10.2. Financial Performance
 - 7.4.10.3. Service Benchmarking
- 7.4.10.4. Strategic Initiatives
- 7.4.11. Catalent Inc.
 - 7.4.11.1. Company Overview
 - 7.4.11.2. Financial Performance
 - 7.4.11.3. Service Benchmarking
 - 7.4.11.4. Strategic Initiatives
- 7.4.12. Samsung Biologics
 - 7.4.12.1. Company Overview
 - 7.4.12.2. Financial Performance
 - 7.4.12.3. Service Benchmarking
 - 7.4.12.4. Strategic Initiatives



List Of Tables

LIST OF TABLES

Table 1 List of Secondary Sources

Table 2 List of Abbreviations

Table 3 North America Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)

Table 4 North America Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)

Table 5 North America Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)

Table 6 North America Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)

Table 7 North America Biotechnology and Pharmaceutical Services Outsourcing by Auditing and Assessment, 2018 - 2030 (USD Million)

Table 8 North America Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)

Table 9 North America Biotechnology and Pharmaceutical Services Outsourcing by Region, 2018 - 2030 (USD Million)

Table 10 North America Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)

Table 11 North America Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)

Table 12 North America Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)

Table 13 North America Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)

Table 14 North America Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)

Table 15 North America Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)

Table 16 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)

Table 17 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)

Table 18 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)



Table 19 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)

Table 20 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Auditing and Assessment, 2018 - 2030 (USD Million)

Table 21 U.S. Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)

Table 22 Canada Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)

Table 23 Canada Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)

Table 24 Canada Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)

Table 25 Canada Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)

Table 26 Canada Biotechnology and Pharmaceutical Services Outsourcing by Auditing and Assessment, 2018 - 2030 (USD Million)

Table 27 Canada Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)

Table 28 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)

Table 29 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)

Table 30 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)

Table 31 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)

Table 32 Mexico Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)

Table 33 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)

Table 34 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)

Table 35 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)

Table 36 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)

Table 37 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by Auditing and Assessment, 2018 - 2030 (USD Million)

Table 38 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by End-



Use, 2018 - 2030 (USD Million)



List Of Figures

LIST OF FIGURES

- Fig. 1 Market research process
- Fig. 2 Data triangulation techniques
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 Value-chain-based sizing & forecasting
- Fig. 6 QFD modeling for market share assessment
- Fig. 7 Market formulation & validation
- Fig. 8 U.S. endoscopy devices market: outlook
- Fig. 9 U.S. endoscopy devices competitive insights
- Fig. 10 Ancillary market outlook
- Fig. 11 Orthopedic digit implants market driver impact
- Fig. 12 Orthopedic digit implants market restraint impact
- Fig. 13 Porter's Analysis
- Fig. 14 PESTLE Analysis
- Fig. 15 U.S. endoscopy devices market: Product outlook and key takeaways
- Fig. 16 U.S. endoscopy devices market: Product movement analysis
- Fig. 17 Endoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 18 Rigid endoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 19 Laparoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 20 Arthroscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 21 Ureteroscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 22 Cystoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 23 Gynecology endoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 24 Neuroendoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 25 Bronchoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 26 Hysteroscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 27 Laryngoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 28 Sinuscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 29 Otoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 30 Sigmoidoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 31 Pharyngoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 32 Duodenoscope market estimates and forecast, 2018 2030 (USD Million)
- Fig. 33 Nasopharyngoscopes market estimates and forecast, 2018 2030 (USD Million)



- Fig. 34 Rhinoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 35 Flexible endoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 36 Laparoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 37 Arthroscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 38 Ureteroscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 39 Cystoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 40 Gynecology endoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 41 Neuroendoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 42 Bronchoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 43 Hysteroscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 44 Laryngoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 45 Sinuscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 46 Otoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 47 Sigmoidoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 48 Pharyngoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 49 Duodenoscope market estimates and forecast, 2018 2030 (USD Million)
- Fig. 50 Nasopharyngoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 51 Rhinoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 52 Colonoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 53 Disposable endoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 54 Laparoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 55 Arthroscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 56 Ureteroscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 57 Cystoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 58 Gynecology endoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 59 Neuroendoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 60 Bronchoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 61 Hysteroscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 62 Laryngoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 63 Sinuscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 64 Otoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 65 Sigmoidoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 66 Pharyngoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 67 Duodenoscope market estimates and forecast, 2018 2030 (USD Million)
- Fig. 68 Nasopharyngoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 69 Rhinoscopes market estimates and forecast, 2018 2030 (USD Million)



- Fig. 70 Colonoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 71 Robot assisted endoscope market estimates and forecast, 2018 2030 (USD Million)
- Fig. 72 Capsule endoscopes market estimates and forecast, 2018 2030 (USD Million)
- Fig. 73 Endoscopy visualization systems market estimates and forecast, 2018 2030 (USD Million)
- Fig. 74 Standard Definition (SD) Visualization Systems market estimates and forecast, 2018 2030 (USD Million)
- Fig. 75 2D Systems market estimates and forecast, 2018 2030 (USD Million)
- Fig. 76 3D Systems market estimates and forecast, 2018 2030 (USD Million)
- Fig. 77 Duodenoscope market estimates and forecast, 2018 2030 (USD Million)
- Fig. 78 High Definition (HD) Visualization Systems market estimates and forecast, 2018 2030 (USD Million)
- Fig. 79 2D Systems market estimates and forecast, 2018 2030 (USD Million)
- Fig. 80 3D Systems market estimates and forecast, 2018 2030 (USD Million)
- Fig. 81 Endoscopy visualization components market estimates and forecast, 2018 2030 (USD Million)
- Fig. 82 Camera heads market estimates and forecast, 2018 2030 (USD Million)
- Fig. 83 Insufflators market estimates and forecast, 2018 2030 (USD Million)
- Fig. 84 Light sources market estimates and forecast, 2018 2030 (USD Million)
- Fig. 85 High-definition monitors market estimates and forecast, 2018 2030 (USD Million)
- Fig. 86 Suction pumps market estimates and forecast, 2018 2030 (USD Million)
- Fig. 87 Video processors market estimates and forecast, 2018 2030 (USD Million)
- Fig. 88 Operative devices market estimates and forecast, 2018 2030 (USD Million)
- Fig. 89 Energy systems market estimates and forecast, 2018 2030 (USD Million)
- Fig. 90 Access devices market estimates and forecast, 2018 2030 (USD Million)
- Fig. 91 Access devices market estimates and forecast, 2018 2030 (USD Million)
- Fig. 92 Suction & Irrigation systems market estimates and forecast, 2018 2030 (USD Million)
- Fig. 93 Hand instruments market estimates and forecast, 2018 2030 (USD Million)
- Fig. 94 Wound retractors market estimates and forecast, 2018 2030 (USD Million)
- Fig. 95 Snares market estimates and forecast, 2018 2030 (USD Million)
- Fig. 96 U.S. endoscopy devices market: End Use outlook and key takeaways
- Fig. 97 U.S. endoscopy devices market: End Use movement analysis
- Fig. 98 Hospitals market estimates and forecast, 2018 2030 (USD Million)
- Fig. 99 Outpatient facilities market estimates and forecast, 2018 2030 (USD Million)
- Fig. 100 Other end-users market estimates and forecast, 2018 2030 (USD Million)
- Fig. 101 Key company categorization



Fig. 102 Heat map analysis, 2023



I would like to order

Product name: North America Biotechnology And Pharmaceutical Services Outsourcing Market Size,

Share & Trends Analysis Report By Service (Consulting, Regulatory Affairs), By End Use,

By Country, And Segment Forecasts, 2024 - 2030

Product link: https://marketpublishers.com/r/N94437D6B1DAEN.html

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/N94437D6B1DAEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970